KIORA PHARMACEUTICALS INC — Director's Dealing 2019

Nov 13, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EYEGATE PHARMACEUTICALS INC (EYEG)
CIK: 0001372514
Period of Report: 2019-11-12

Reporting Person: GOLDBERG MORTON (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-11-12	Common Stock	S	2001	$4.29	Disposed	1961	Direct

Footnotes

F1: Effective as of 08/30/2019, the Issuer effected a 1-for-15 reverse split of its common stock. The number of shares reflects the reverse stock split.